Altamira Therapeutics Announces Reverse Stock Split
HAMILTON, BERMUDA , Oct. 24, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that...
Clinical Trial
Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
MIAMI, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
Motus GI Announces Positive Clinical Data for Pure-Vu EVS in Three Poster Presentations at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
Positive clinical data from feasibility and efficacy study of the Pure-Vu EVS conducted by Minneapolis VA Health Care System Overview...
SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022
Cumulative interim analysis of outcomes by fungal disease type highlighted in a platform presentation demonstrates 82.3% positive clinical outcomes in...
Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting
- Clinical and in vitro data presented in three late-breaking presentations at ATA provide emerging evidence of VRDN-001 efficacy and...
Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology
- Medicines and Healthcare products Regulatory Agency of the United Kingdom approves clinical trial in squamous cell carcinoma of the...
Inventiva announces a scientific presentation at the AASLD The Liver Meeting® 2022
Daix (France), Long Island City (New York, United States), October 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a...
BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing
BriaCell has successfully completed its Phase I safety and tolerability evaluation of Bria-IMT™ in combination with Incyte’s retifanlimab in advanced...
Avricore to Present at Emerging Growth Conference on Oct. 26, 2022
VANCOUVER, British Columbia, Oct. 21, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) is excited to...
Altamira Therapeutics Announces Divestiture of Inner Ear Development Assets
HAMILTON, BERMUDA , Oct. 21, 2022 (GLOBE NEWSWIRE) -- Definitive agreement to sell 90% stake in Company’s Zilentin subsidiary with...
Allied Corp. Announces Completion of First THC Flower Harvests Now Offered for Sale and Export From Colombia
KELOWNA, British Columbia, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to...
EPI Health, a Novan Company, and MC2 Therapeutics Announce Data from Survey Conducted by National Psoriasis Foundation Presented at 42nd Annual Fall Clinical Dermatology Conference®
Data collected shows importance of treatment formulation characteristics and speed of improvement in psoriasis symptoms to patient treatment adherenceDURHAM, N.C....
EPI Health, a Novan Company, and MC2 Therapeutics Present New Data In Multiple Posters Highlighting WYNZORA’s® Unique PAD Technology™ at the 42nd Annual Fall Clinical Dermatology Conference®
Research shows PAD (Polyaphron Dispersion) Technology™ leads to more efficient delivery of Calcipotriene (CAL) and Betamethasone Dipropionate (BDP) than CAL/BDP topical...
CinCor Pharma Announces Publication of Phase 1 Multiple Ascending Dose Study Data in Hypertension Research
WALTHAM, Mass., Oct. 21, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced the publication of Phase 1...
Nighthawk Biosciences’ Scorpion Subsidiary Announces Grand Opening of its San Antonio Facility
DURHAM, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing...
NeuBase Therapeutics Announces Gene Editing Research Agreement with Global Healthcare Company
PITTSBURGH, Oct. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company...
Microbot Medical Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
HINGHAM, Mass., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into...
Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90%
Study Design EnACT Phase 2 DesignTwo-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203 Mean...
Sientra Announces Pricing of $13.2 Million Public Offering
SANTA BARBARA, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics...
Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022
Presentation highlights a greater than 60% reduction in acute exacerbations and need for antibiotics for chronic sinusitis patients who used...